Are you a patient?
Click here
to learn more about Myopia.
About
Management
Pipeline
Why Myopia?
News
About
Management
Pipeline
Why Myopia?
News
Contact
Sydnexis is decreasing myopic progression in children.
See How
Sydnexis is decreasing myopic progression in children.
See How
A novel, stable, & comfortable topical eyedrop used once daily at bedtime.
See How
Treating Myopia with the STAR Study
A Phase 3 study to treat the progression of myopia in children.
Learn More
Are you a patient?
Learn more about Myopia & how to treat it.
Click Here
Latest News
Sydnexis Completes Enrollment in Phase 3 Clinical Trial
See more at ClinicalTrials.gov.
Read More
May 15, 2021
Sydnexis Secures $45 Million Series B
Financing Led by Visionary Ventures and Bluestem Capital
Read More
August 10, 2021
Previous News